Part 1: Response Evaluation Based on PSA (Prostate Specific Antigen ): Percentage Change From Baseline to End of Study.Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements.Part 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage.Part 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result.Part 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result.Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC) ĭata is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC).Part 2: Number of Participants Who Experienced a Neuropathy Event.Part 1: Number of Participants Who Experienced a Neuropathy Event.Part 2: Number of Participants Who Experienced a Bleeding Event.Part 1: Number of Participants Who Experienced a Bleeding Event.
SAVA YAHOO FINANCE SKIN
The above is my personal opinion and it is based primarily on the analysis of SAVA’s stock chart. If it is a short squeeze, the stock could get back to $100 in a very short timeframe, and if the FDA approves their Alzheimer’s drug, we would expect the stock to go to $300 or more.Ĭassava Sciences (SAVA) is a VERY SPECULATIVE STOCK – Meaning that you are in essence “gambling” if you buy it, because you could lose part or all of your investment. 16, 2022, reported that SAVA stock soared after it was disclosed that board member and well known investor, Sanford Robertson, just bought 100,000 shares of the stock, worth over $2 Million. Secondly, reports that there are only 40.1 Million shares outstanding, and only a Float of 37.4 Million shares, and 11.43 Million shares sold Short, as of July 29, 2022, which is equal to 30.20% of the FLOAT….which is a HUGE percentage for such a thinly traded stock.Īnd thirdly, on Aug. Some skeptics say that the company manipulated the data, but we personally don’t believe it. We bought it last week, and think it is a prime candidate for a short squeeze.įirst of all, Cassava has a drug in 3rd Phase trials that seems to have the potential to actually improve the cognition of Alzheimer’s patients, not just slow the progression of the disease. Wednesday, it is already up $2.63 from yesterday’s close of $25.31, see chart below. The stock we are featuring today is Cassava Sciences (SAVA). However, there are still great opportunities to make lots of money…especially buying stocks that are in a short squeeze. Lots of money was made by the traders with courage and brains. The Market (The DOW) is now up about 158 points at 12:11p.m., a great needed rally after it fell about 900 points in the last 3 days.Īs we wrote on July 4th, we continue to maintain that the Bear Market ended a couple of months ago. Market Assessment – As of Wednesday, August 24 at 12:11 p.m.
0 kommentar(er)
